<DOC>
	<DOCNO>NCT01814709</DOCNO>
	<brief_summary>This open-label , two-arm , drug interaction study investigate effect co-administration rifampin itraconazole pharmacokinetics GDC-0032 healthy volunteer . In Arm A , volunteer receive GDC-0032 rifampin ; Arm B , volunteer receive GDC-0032 itraconazole . The anticipated time study treatment approximately 30 day .</brief_summary>
	<brief_title>A Drug Interaction Study GDC-0032 Co-administered With Rifampin Itraconazole Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Female volunteer nonpregnant , nonlactating , either postmenopausal least 1 year surgically sterile Male volunteer either sterile , agree use adequate method contraception Body mass index ( BMI ) range 18 32 kg/m2 , inclusive No clinically significant finding medical history , physical examination , 12lead ECG , vital sign ; clinical laboratory evaluation Negative hepatitis B virus , hepatitis C virus negative HIV antibody screen Significant history clinical manifestation significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder History significant hypersensitivity , intolerance , allergy drug compound , food , substance History stomach intestinal surgery resection would alter absorption and/or excretion orally administer study drug History alcoholism drug addiction within 1 year prior Checkin History chronic proton pump inhibitor ( PPI ) use within 6 month Checkin , use PPIs , H2receptor antagonists , antacid within 1 month prior Checkin entire study Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis History type 1 2 diabetes and/or elevate fast glucose baseline Malabsorption syndrome condition would interfere enteral absorption Use tobacco nicotine containing product Participation investigational study drug biologic agent trial receipt investigational study drug occur within 5 halflives 30 day , whichever long Checkin entire study duration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>